Terminal Complement Inhibition and Control of Hemolysis in Paroxysmal Nocturnal Hemoglobinuria Following Switching from High-Dose Eculizumab to Ravulizumab …
M Griffin, S Gandhi, E Hicks, D Jain, R Kelly, T Munir… - Blood, 2022 - ashpublications.org
Background: Intravenous (IV) complement component 5 (C5) inhibitors, eculizumab and
ravulizumab, are the current standards of care in patients with paroxysmal nocturnal …
ravulizumab, are the current standards of care in patients with paroxysmal nocturnal …
Ravulizumab in paroxysmal nocturnal hemoglobinuria: a profile of its use
K McKeage, KA Lyseng-Williamson - Drugs & Therapy Perspectives, 2019 - Springer
Ravulizumab (Ultomiris™) is a humanized monoclonal antibody that inhibits terminal
complement C5, thereby reducing hemolysis, inflammation, and thrombosis in patients with …
complement C5, thereby reducing hemolysis, inflammation, and thrombosis in patients with …
[HTML][HTML] Ravulizumab (ALXN1210) versus eculizumab in adults with paroxysmal nocturnal hemoglobinuria: pharmacokinetics and pharmacodynamics observed in …
RP De Latour, RA Brodsky, S Ortiz, AM Risitano… - Blood, 2018 - Elsevier
Abstract Background/Objective: In 2 large, phase 3 clinical studies, ravulizumab
(ALXN1210), an innovative C5 inhibitor administered every 8 weeks, achieved noninferiority …
(ALXN1210), an innovative C5 inhibitor administered every 8 weeks, achieved noninferiority …
P812: Long-term complement inhibition and survival outcomes in patients with paroxysmal nocturnal hemoglobinuria: An interim analysis of the ravulizumab clinical …
A Kulasekararaj, R Brodsky, M Griffin, A Kulagin… - …, 2022 - journals.lww.com
Background: Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, chronic, hematologic
disorder characterized by uncontrolled terminal complement activation, intravascular …
disorder characterized by uncontrolled terminal complement activation, intravascular …
[HTML][HTML] A phase 3 study of ravulizumab (ALXN1210) versus eculizumab in adults with paroxysmal nocturnal hemoglobinuria naive to complement inhibitors: results of …
IC Weitz, A Kulagin, S Nakao, CI Piatek, J Szer… - Blood, 2018 - Elsevier
Abstract Background/Objective: Ravulizumab (ALXN1210) is an innovative C5 inhibitor with
high C5 affinity and a half-life approximately 4 times longer than eculizumab. In the largest …
high C5 affinity and a half-life approximately 4 times longer than eculizumab. In the largest …
One-year efficacy and safety of ravulizumab in adults with paroxysmal nocturnal hemoglobinuria naïve to complement inhibitor therapy: open-label extension of a …
H Schrezenmeier, A Kulasekararaj… - Therapeutic …, 2020 - journals.sagepub.com
Background: Ravulizumab, the only long-acting complement C5 inhibitor for adults with
paroxysmal nocturnal hemoglobinuria (PNH), demonstrated non-inferiority to eculizumab …
paroxysmal nocturnal hemoglobinuria (PNH), demonstrated non-inferiority to eculizumab …
Complement inhibition in paroxysmal nocturnal hemoglobinuria: From biology to therapy
F Versino, B Fattizzo - International Journal of Laboratory …, 2024 - Wiley Online Library
Complement inhibitors are the mainstay of paroxysmal nocturnal hemoglobinuria (PNH)
treatment. The anti‐C5 monoclonal antibody eculizumab was the first treatment to improve …
treatment. The anti‐C5 monoclonal antibody eculizumab was the first treatment to improve …
[HTML][HTML] One-year efficacy and safety from a phase 3 trial of ravulizumab in adult patients with paroxysmal nocturnal hemoglobinuria receiving prior eculizumab …
A Kulasekararaj, A Hill, S Langemeijer, RA Wells… - Blood, 2019 - Elsevier
INTRODUCTION Ravulizumab, an innovative long-acting C5 complement inhibitor, was
recently approved in the United States, Europe, and Japan for the treatment of paroxysmal …
recently approved in the United States, Europe, and Japan for the treatment of paroxysmal …
Ravulizumab (ALXN1210) in patients with paroxysmal nocturnal hemoglobinuria: results of 2 phase 1b/2 studies
A Röth, ST Rottinghaus, A Hill, ES Bachman… - Blood …, 2018 - ashpublications.org
Abstract Ravulizumab (ALXN1210), a humanized monoclonal antibody to complement
component C5, was engineered from eculizumab to have a substantially longer terminal half …
component C5, was engineered from eculizumab to have a substantially longer terminal half …
Ravulizumab for the treatment of paroxysmal nocturnal hemoglobinuria
JW Lee, AG Kulasekararaj - Expert Opinion on Biological Therapy, 2020 - Taylor & Francis
Introduction: Eculizumab, which is indicated to treat patients with paroxysmal nocturnal
hemoglobinuria (PNH), is a life-changing, life-saving therapy that decreases intravascular …
hemoglobinuria (PNH), is a life-changing, life-saving therapy that decreases intravascular …